Recent Developments on Vinay Prasad’s Leaked FDA Memo, Alzheimer’s Disease Updates, and Next-Gen Obesity Drugs
Vinay Prasad FDA memo; COVID-19 vaccine deaths children; FDA vaccine approval changes; Alzheimer’s disease research 2025; obesity drugs next generation; COVID-19 vaccine safety controversy; FDA vaccine policy overhaul
Recent obesity and IL-6 program updates for Fractyl, Helicore, and Tiziana
Fractyl Health; Revita; REVEAL-1; weight loss maintenance; GLP-1 discontinuation; Helicore; Tiziana Life Sciences; IL-6; autoimmune; obesity
Imvax Shares Positive Phase 2b Data for IGV-001 Glioblastoma Treatment and Plans FDA Meeting
Imvax; IGV-001; glioblastoma; Phase 2b trial; overall survival; FDA meeting; immunotherapy; clinical trial; glioblastoma treatment
Top Drug Regulator Richard Pazdur to Retire from FDA Amid Industry Concerns
Richard Pazdur; FDA; retirement; Center for Drug Evaluation and Research; drug regulation; Marty Makary; leadership turnover
Alkeus Pharmaceuticals Appoints Carlos Quezada-Ruiz as Chief Medical Officer
Alkeus Pharmaceuticals; Carlos Quezada-Ruiz; Chief Medical Officer; Stargardt disease; gildeuretinol; retinal diseases; ophthalmology; clinical research; biopharmaceutical leadership
ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial on December 3, 2025
ADC Therapeutics; LOTIS-7; clinical trial update; ZYNLONTA; Phase 1b trial; loncastuximab tesirine; safety; efficacy; corporate webcast
Tessera Therapeutics Strikes $150M Partnership with Regeneron for Gene Writing Therapy
Tessera Therapeutics; Regeneron; gene writing; TSRA-196; AATD; alpha-1 antitrypsin deficiency; gene therapy; partnership; investment
Lilly Slightly Lowers Self-Pay Prices for Single-Dose Vials of Zepbound
Eli Lilly; Zepbound; price cut; self-pay; single-dose vials; direct-to-consumer; LillyDirect; obesity drug; GLP-1
UK Agrees to Increase Drug Spending by 25% to Avoid US Pharma Tariffs
UK; United States; drug spending; pharmaceutical tariffs; trade deal; medicine pricing; Trump administration; pharma companies
Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Data in Leptomeningeal Metastases at SABCS 2025
Plus Therapeutics; ReSPECT-LM; Phase 1; dose escalation; REYOBIQ; leptomeningeal metastases; San Antonio Breast Cancer Symposium; SABCS 2025; poster spotlight; central nervous system cancers; radiotherapeutics